ClinicalTrials.gg
CompletedNCT03056755BYLieveUpdated Jan 13, 2026Results posted

Study Assessing the Efficacy and Safety of Alpelisib Plus Fulvestrant or Letrozole, Based on Prior Endocrine Therapy, in Patients With PIK3CA Mutant, HR+, HER2- Advanced Breast Cancer Who Have Progressed on or After Prior Treatments

A Phase 2 interventional study of Alpelisib and Fulvestrant in Breast Cancer, sponsored by Novartis Pharmaceuticals. Completed at 94 sites in 19 countries. Open to participants aged 18 Years to 99 Years. Per ClinicalTrials.gov, last updated 2026-01-13.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
383
Allocation
Non-randomized
Ages
18 Years to 99 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 38 studies testing alpelisib in Breast Neoplasms — 3 open to participants now, 12 under way, 2 of them phase 3. Alpelisib · Breast Neoplasms.

Enrollment
2nd of 38
383 · median 44
Started
2017
the only one that year
Phase 2
15 of 38
2 open now
Registered
18th of 38
by date
Lead sponsor
18 of 38
Novartis Pharmaceuticals

Among the 38 studies testing alpelisib in Breast Neoplasms, this one is the 2nd largest by enrollment, is the only one that started in 2017, is one of 15 in phase 2, and was the 18th registered.

Breast Neoplasms

14,837 studies on the registry are indexed under Breast Neoplasms; 3,320 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

3 of the 38 studies testing alpelisib in Breast Neoplasms are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About alpelisib

Alpelisib: first FDA approval 2019 (PIQRAY), first EMA approval 2020. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 2,399 Breast Neoplasms studies recruiting now, 1,570 (65%) set no upper age limit and 592 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.

This study: 18 Years to 99 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 38 studies testing alpelisib in Breast Neoplasms, or all of them as a file.
02

Study summary

This was a Phase II, multicenter, open-label, three-cohort, non-comparative study of alpelisib plus endocrine therapy (either fulvestrant or letrozole) in subjects (pre- and post-menopausal women and men) with HR-positive, HER2-negative aBC harboring PIK3CA mutation(s) in the tumor, whose disease had progressed on or after prior treatments.

Read the detailed description

The study comprised two phases:

  1. Core Phase: included a treatment phase for all subjects from first subject first treatment (FSFT) until disease progression, unacceptable toxicity, or death until 18 months post last subject first treatment (LSFT) + 1 month safety follow-up (total 19 months post LSFT), discontinuation from the study treatment for any other reason, or sponsor terminates the study. At the start of the Core Phase, subjects were assigned to Cohort A, Cohort B, or Cohort C based on previous therapy as follows:

    • Cohort A: alpelisib (300 mg oral QD) + fulvestrant (500 mg intramuscular (IM)) to subjects whose last prior treatment was a CDK4/6i plus any AI;
    • Cohort B: alpelisib (300 mg oral QD) + letrozole (2.5 mg oral QD) to subjects whose last prior treatment was a CDK4/6i plus fulvestrant;
    • Cohort C: alpelisib (300 mg oral QD)+ fulvestrant (500 mg IM) to subjects who failed prior AI based therapy and whose last prior treatment was systemic chemotherapy or endocrine therapy (as monotherapy or in combination with targeted treatment except CDK 4/6i + AI). Endocrine therapy included letrozole, fulvestrant and CDK 4/6 inhibitor plus fulvestrant.
  2. Extension Phase: included a treatment phase starting at the end of the treatment Core Phase until last subject last visit(LSLV) (up to 36 months). Following the end of the Core Phase, subjects continuing to derive benefit from study treatment who were not eligible for Post-Study Drug Supply (PSDS) in their country based on local regulations were re-consented and transitioned to the Extension Phase. Subjects continued on their existing study treatment assigned in the Core Phase until disease progression/lack of clinical benefit or any other reason for which the subject may have been discontinued from study treatment. If PSDS became available for a subject, the subject was to be discontinued from the study and to access treatment via PSDS. When subjects discontinued treatment for any reason, the end of treatment visit was performed after discontinuation of the medication , followed by safety follow-up 30 days after last dose.

A total of 340 subjects were planned to be enrolled, with approximately 112 subjects in each cohort. In the Core Phase, 379 subjects were analyzed, with 127 subjects in Cohort A, 126 subjects in Cohort B, and 126 subjects in Cohort C. In the Extension Phase, 11 subjects were analyzed, with 1 subject in Cohort A and 10 subjects in Cohort C.

03

Conditions studied

  • Breast Cancer

Browse trials for

Keywords

  • advanced breast cancer
  • PIK3CA
  • CDK 4/6 inhibitor
  • fulvestrant
  • letrozole
  • HR+
  • HER2-negative
  • post menopausal
  • pre-menopausal
  • aromatase inhibitor
  • endocrine treatment
  • AI
  • ET
04

Who can participate

Ages eligible
18 Years to 99 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria: Subjects eligible for inclusion in the Core Phase of the study fulfilled the following key inclusion criteria:

  • Subject was an adult male or female ≥ 18 years of age.
  • Subjects with and/or cytologically confirmed diagnosis of estrogen receptor (ER)-positive and/or progesterone receptor (PgR)-positive breast cancer by local laboratory.
  • Subjects with a confirmed human epidermal growth factor receptor-2 ()-negative aBC.
  • Subjects with gene encoding the p110alpha catalytic subunit of PI3K (phosphatidylinositol-3-kinase) (PIK3CA) mutation.
  • In case of women, both premenopausal and subjects were allowed to be included in this study.
  • Subjects with documented evidence of tumor progression on or after:

    i. Cyclin-Dependent Kinase 4 and 6 inhibitor (CDK4/6i) treatment as last treatment regimen in Cohorts A and B.

ii. aromatase inhibitor (AI) treatment (either in or setting) and received systemic chemotherapy or ET (monotherapy or combination except CDK4/6i + AI) as last treatment regimen in Cohort C. Upon completion of enrollment of Cohort B, subjects who received CDK4/6i + fulvestrant as immediate prior therapy were eligible for Cohort C.

iii. No more than 2 prior anticancer therapies for aBC. iv. Received no more than 1 prior regimen of chemotherapy for the treatment of advanced/metastatic disease was permitted.

v. Recovered to grade 1 or better from any adverse events (AEs) related to previous anticancer therapy prior to study entry (except alopecia or other toxicities not considered a safety risk for the subject at the investigator's discretion).

  • Subjects with:

    i. , i.e., at least 1 measurable lesion as per v1.1 criteria; or ii. If no measurable disease was present, at least 1 predominantly lytic bone lesion had to be present.

  • Subjects with adequate bone marrow and coagulation function, liver function and renal function as shown by laboratory values.
  • Subjects with (ECOG) performance status score of ≤ 2.

Key exclusion criteria were:

  • Subjects with a known to alpelisib, fulvestrant, letrozole, goserelin, or leuprolide or to any of their .
  • Subjects with prior treatment with any PI3K inhibitor (PI3Ki).
  • Subjects with central nervous system (CNS) involvement unless they met all of the following criteria:

    i. At least 4 weeks from prior therapy completion (including radiation and/or surgery) to starting the study treatment, ii. Clinically stable CNS tumor at the time of screening untreated or without evidence of progressions for at least 4 weeks after treatment as determined by clinical examination and brain imaging (magnetic resonance imaging (MRI) or computed tomography (CT) during screening period and stable low dose of for 2 weeks prior to initiating study treatment.

  • Subjects with an established diagnosis of diabetes mellitus type I or uncontrolled type II.
  • Any concurrent severe and/or uncontrolled medical conditions that would, in the investigator's judgment, contraindicate subject participation in the study (e.g., chronic active hepatitis, severe hepatic impairment, etc.).
  • Subjects with a history of noncompliance to medical regimens.
  • Subjects with impairment of gastrointestinal (GI) function or GI disease that could significantly alter the absorption of the study drugs based on investigator discretion.
  • Subjects with documented pneumonitis/interstitial lung disease which was active and requiring treatment.
  • Subjects concurrently using other anticancer therapy. All anticancer therapy had to be discontinued prior to Day 1 of study treatment.
  • Subjects who had major surgery within 14 days prior to starting treatment with alpelisib, or did not recover from major side effects.
  • Subjects with significant cardiac abnormalities.
  • History of acute pancreatitis within 1 year of screening or past medical history of chronic pancreatitis.
  • Subjects who did not use highly effective while on alpelisib and through the duration after the final dose of alpelisib (not applicable to postmenopausal women).
  • Subjects with unresolved osteonecrosis of the jaw.

Other inclusion/exclusion criteria may apply

Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
383 participants (actual)

Study arms

  • Experimental
    Cohort A: Pre-treated with CDK 4/6i + AI

    Participants who received any Cyclin-Dependent Kinases 4 and 6 inhibitor (CDK 4/6i) plus aromatase inhibitor (AI) as immediate prior treatment will receive alpelisib + fulvestrant

    Drug: Alpelisib · Drug: Fulvestrant · Drug: Goserelin · Drug: Leuprolide

  • Experimental
    Cohort B: Pre-treated with CDK 4/6i + fulvestrant

    Patients who received any CDK 4/6i plus fulvestrant as immediate prior treatment will receive alpelisib + letrozole

    Drug: Alpelisib · Drug: Letrozole · Drug: Goserelin · Drug: Leuprolide

  • Experimental
    Cohort C: Pre-treated with systemic chemotherapy or ET

    Participants who received systemic chemotherapy or endocrine therapy (ET) (as monotherapy or in combination with targeted treatment except CDK 4/6i + AI) as immediate prior treatment will receive alpelisib + fulvestrant.

    Drug: Alpelisib · Drug: Fulvestrant · Drug: Goserelin · Drug: Leuprolide

Interventions

  • 300 mg of alpelisib film-coated tablets administered orally once daily

    Also known as: BYL719

  • 500 mg of fulvestrant via intramuscular injection administered on Days 1, 15 on Cycle 1 and Day 1 at each cycle thereafter. Cycle=28 days

  • 2.5 mg of letrozole film-coated tablets administered orally once daily

  • 3.6 mg of goserelin via injectable subcutaneous implant administered every 28 days. Only for men in Cohort B and premenopausal women.

  • 7.5 mg of leuprolide via injectable intramuscular depot administered every 28 days. Only for men in cohort B and premenopausal women.

06

What researchers measure

Primary outcomes

  1. Core Phase: Percentage of Participants Who Were Alive Without Disease Progression at 6 Months

    Percentage of participants who were alive without disease progression at 6-month follow-up based on local investigator assessment per RECIST v1.1 in Cohort A, Cohort B and Cohort C. Participants who progressed, died, or discontinued study before 6 months were counted as a failure.

    Time frame: At 6 months

Secondary outcomes

  1. Core Phase: Progression Free Survival (PFS)

    PFS is defined as the time from the date of first dose of study medication to the date of the first documented progression or death due to any cause occurring in the study. PFS was assessed based on local investigator's assessment according to RECIST v1.1. PFS was censored if no PFS event was observed before the cut-off date. The censoring date was the date of last adequate tumor assessment before the cut-off date. If a PFS event was observed after two or more missing or non-adequate tumor assessments, then PFS was censored at the last adequate tumor assessment. PFS was estimated using the Kaplan-Meier method.

    Time frame: From date of first dose to date of first documented progression or death, up to 46 months

  2. Core Phase: Progression Free Survival on Next Line Treatment (PFS2)

    PFS2 is defined as time from the date of first dose of study medication to the date of first documented progression on next-line therapy or death from any cause. The first documented progression on next-line treatment is based on investigator assessment of progressive disease. PFS2 was estimated using the Kaplan-Meier method.

    Time frame: From date of first dose to date of first documented progression on next-line therapy or death, up to approximately 55 months

  3. Core Phase: Overall Response Rate (ORR)

    ORR is defined as the percentage of participants with best overall response (BOR) of complete response (CR) or partial response (PR) based on local investigator's assessment according to RECIST v1.1 in each cohort. CR: Disappearance of all non-nodal target lesions and all non-target lesions. In addition, any pathological lymph nodes assigned as target lesions must have a reduction in short axis to \< 10 mm and all lymph nodes assigned as non-target lesions must be non-pathological in size (\<10 mm short axis) PR: At least a 30% decrease in the sum of diameter of all target lesions, taking as reference the baseline sum of diameters.

    Time frame: Up to 46 months

  4. Core Phase: Clinical Benefit Rate (CBR)

    CBR is defined as the percentage of participants with a BOR of CR or PR or an overall lesion response of stable disease (SD) or Non-CR/ Non-PD lasting ≥ 24 weeks based on local investigator's assessment according to RECIST v1.1. CR: Disappearance of all non-nodal target lesions and all non-target lesions. In addition, any pathological lymph nodes assigned as target lesions must have a reduction in short axis to \< 10 mm and all lymph nodes assigned as non-target lesions must be non-pathological in size (\<10 mm short axis) PR: At least a 30% decrease in the sum of diameter of all target lesions, taking as reference the baseline sum of diameters. SD: Neither sufficient shrinkage to qualify for PR or CR nor an increase in lesions which would qualify for progressive disease.

    Time frame: Up to 46 months

  5. Core Phase: Duration of Response (DOR)

    DOR is the time from the date of first documented response (confirmed CR or PR based on local investigator's assessment according to RECIST v1.1) to the date of first documented progression or death due to underlying cancer. Subjects continuing without progression or death due to underlying cancer were censored at the date of their last adequate tumor assessment. DOR was estimated using the Kaplan-Meier method.

    Time frame: From date of first documented response to first documented progression or death, up to 33.3 months

  6. Core Phase: Overall Survival (OS)

    OS is defined as the time of start of treatment to date of death or lost to follow-up. If a subject was not known to have died, then the OS data was censored at the date of the last known alive status for the patient.

    Time frame: From date of first dose and up to approximately 55 months

  7. Extension Phase: Percentage of Participants With Clinical Benefit as Assessed by the Investigator During the Extension Phase

    Clinical Benefit Rate, as assessed by the Investigator during the Extension Phase, was defined as the proportion of patients with a best overall response of Complete Response (CR) or Partial Response (PR), or an overall lesion response of Stable Disease (SD) or non-complete response/non-progressive disease that lasted at least 24 weeks, based on the local investigator's assessment according to Response Evaluation Criteria in Solid Tumors version 1.1.

    Time frame: Day 1 of each extension cycle up to Cycle 29 (each cycle lasting 28 days); median duration of exposure to study treatment (alpelisib or fulvestrant) = 41 months

07

Results

Posted Mar 27, 2024

Participant flow

This study was conducted in 92 centers across 19 countries

Core Phase
Participant flow — Core Phase
MilestoneCohort A: Pre-treated With CDK 4/6i + AICohort B: Pre-treated With CDK 4/6i + FulvestrantCohort C: Pre-treated With Systemic Chemotherapy or ET
Started127126126
Completed1010
Not completed126126116
Withdrew: Progressive disease898890
Withdrew: Adverse event201413
Withdrew: Physician decision7135
Withdrew: Subject/guardian decision584
Withdrew: Death324
Withdrew: Protocol deviation110
Withdrew: Technical problems100
Extension Phase
Participant flow — Extension Phase
MilestoneCohort A: Pre-treated With CDK 4/6i + AICohort B: Pre-treated With CDK 4/6i + FulvestrantCohort C: Pre-treated With Systemic Chemotherapy or ET
Started1010
Completed005
Not completed105
Withdrew: Physician decision103
Withdrew: Adverse event001
Withdrew: Subject/guardian decision001

Outcome measures

PrimaryCore Phase: Percentage of Participants Who Were Alive Without Disease Progression at 6 Months

Percentage of participants who were alive without disease progression at 6-month follow-up based on local investigator assessment per RECIST v1.1 in Cohort A, Cohort B and Cohort C. Participants who progressed, died, or discontinued study before 6 months were counted as a failure.

Time frame:
At 6 months
Reported as:
Number · Percentage of participants
Core Phase: Percentage of Participants Who Were Alive Without Disease Progression at 6 Months
Percentage of participantsCohort A: Pre-treated With CDK 4/6i + AICohort B: Pre-treated With CDK 4/6i + FulvestrantCohort C: Pre-treated With Systemic Chemotherapy or ET
Core Phase: Percentage of Participants Who Were Alive Without Disease Progression at 6 Months53.8 (44.41 to 62.96)46.5 (37.10 to 56.07)53.0 (43.51 to 62.41)
SecondaryCore Phase: Progression Free Survival (PFS)

PFS is defined as the time from the date of first dose of study medication to the date of the first documented progression or death due to any cause occurring in the study. PFS was assessed based on local investigator's assessment according to RECIST v1.1. PFS was censored if no PFS event was observed before the cut-off date. The censoring date was the date of last adequate tumor assessment before the cut-off date. If a PFS event was observed after two or more missing or non-adequate tumor assessments, then PFS was censored at the last adequate tumor assessment. PFS was estimated using the Kaplan-Meier method.

Time frame:
From date of first dose to date of first documented progression or death, up to 46 months
Reported as:
Median · Months
Core Phase: Progression Free Survival (PFS)
MonthsCohort A: Pre-treated With CDK 4/6i + AICohort B: Pre-treated With CDK 4/6i + FulvestrantCohort C: Pre-treated With Systemic Chemotherapy or ET
Core Phase: Progression Free Survival (PFS)8.0 (5.6 to 8.6)5.6 (3.7 to 7.1)5.6 (5.4 to 8.1)
SecondaryCore Phase: Progression Free Survival on Next Line Treatment (PFS2)

PFS2 is defined as time from the date of first dose of study medication to the date of first documented progression on next-line therapy or death from any cause. The first documented progression on next-line treatment is based on investigator assessment of progressive disease. PFS2 was estimated using the Kaplan-Meier method.

Time frame:
From date of first dose to date of first documented progression on next-line therapy or death, up to approximately 55 months
Reported as:
Median · Months
Core Phase: Progression Free Survival on Next Line Treatment (PFS2)
MonthsCohort A: Pre-treated With CDK 4/6i + AICohort B: Pre-treated With CDK 4/6i + FulvestrantCohort C: Pre-treated With Systemic Chemotherapy or ET
Core Phase: Progression Free Survival on Next Line Treatment (PFS2)15.2 (11.4 to 21.7)13.0 (10.2 to 13.9)13.5 (11.5 to 17.3)
SecondaryCore Phase: Overall Response Rate (ORR)

ORR is defined as the percentage of participants with best overall response (BOR) of complete response (CR) or partial response (PR) based on local investigator's assessment according to RECIST v1.1 in each cohort. CR: Disappearance of all non-nodal target lesions and all non-target lesions. In addition, any pathological lymph nodes assigned as target lesions must have a reduction in short axis to \< 10 mm and all lymph nodes assigned as non-target lesions must be non-pathological in size (\<10 mm short axis) PR: At least a 30% decrease in the sum of diameter of all target lesions, taking as reference the baseline sum of diameters.

Time frame:
Up to 46 months
Reported as:
Number · Percentage of participants
Core Phase: Overall Response Rate (ORR)
Percentage of participantsCohort A: Pre-treated With CDK 4/6i + AICohort B: Pre-treated With CDK 4/6i + FulvestrantCohort C: Pre-treated With Systemic Chemotherapy or ET
Core Phase: Overall Response Rate (ORR)19.3 (12.7 to 27.6)17.5 (11.1 to 25.8)25.2 (17.6 to 34.2)
SecondaryCore Phase: Clinical Benefit Rate (CBR)

CBR is defined as the percentage of participants with a BOR of CR or PR or an overall lesion response of stable disease (SD) or Non-CR/ Non-PD lasting ≥ 24 weeks based on local investigator's assessment according to RECIST v1.1. CR: Disappearance of all non-nodal target lesions and all non-target lesions. In addition, any pathological lymph nodes assigned as target lesions must have a reduction in short axis to \< 10 mm and all lymph nodes assigned as non-target lesions must be non-pathological in size (\<10 mm short axis) PR: At least a 30% decrease in the sum of diameter of all target lesions, taking as reference the baseline sum of diameters. SD: Neither sufficient shrinkage to qualify for PR or CR nor an increase in lesions which would qualify for progressive disease.

Time frame:
Up to 46 months
Reported as:
Number · Percentage of participants
Core Phase: Clinical Benefit Rate (CBR)
Percentage of participantsCohort A: Pre-treated With CDK 4/6i + AICohort B: Pre-treated With CDK 4/6i + FulvestrantCohort C: Pre-treated With Systemic Chemotherapy or ET
Core Phase: Clinical Benefit Rate (CBR)46.2 (37.0 to 55.6)35.1 (26.4 to 44.6)38.3 (29.4 to 47.8)
SecondaryCore Phase: Duration of Response (DOR)

DOR is the time from the date of first documented response (confirmed CR or PR based on local investigator's assessment according to RECIST v1.1) to the date of first documented progression or death due to underlying cancer. Subjects continuing without progression or death due to underlying cancer were censored at the date of their last adequate tumor assessment. DOR was estimated using the Kaplan-Meier method.

Time frame:
From date of first documented response to first documented progression or death, up to 33.3 months
Reported as:
Median · Months
Core Phase: Duration of Response (DOR)
MonthsCohort A: Pre-treated With CDK 4/6i + AICohort B: Pre-treated With CDK 4/6i + FulvestrantCohort C: Pre-treated With Systemic Chemotherapy or ET
Core Phase: Duration of Response (DOR)13.8 (5.5 to 19.4)6.5 (5.4 to 9.4)16.5 (8.3 to 22.2)
SecondaryCore Phase: Overall Survival (OS)

OS is defined as the time of start of treatment to date of death or lost to follow-up. If a subject was not known to have died, then the OS data was censored at the date of the last known alive status for the patient.

Time frame:
From date of first dose and up to approximately 55 months
Reported as:
Median · Months
Core Phase: Overall Survival (OS)
MonthsCohort A: Pre-treated With CDK 4/6i + AICohort B: Pre-treated With CDK 4/6i + FulvestrantCohort C: Pre-treated With Systemic Chemotherapy or ET
Core Phase: Overall Survival (OS)27.3 (21.3 to 32.7)29.0 (24.5 to 34.8)20.7 (16.9 to 28.1)
SecondaryExtension Phase: Percentage of Participants With Clinical Benefit as Assessed by the Investigator During the Extension Phase

Clinical Benefit Rate, as assessed by the Investigator during the Extension Phase, was defined as the proportion of patients with a best overall response of Complete Response (CR) or Partial Response (PR), or an overall lesion response of Stable Disease (SD) or non-complete response/non-progressive disease that lasted at least 24 weeks, based on the local investigator's assessment according to Response Evaluation Criteria in Solid Tumors version 1.1.

Time frame:
Day 1 of each extension cycle up to Cycle 29 (each cycle lasting 28 days); median duration of exposure to study treatment (alpelisib or fulvestrant) = 41 months
Reported as:
Count of participants · Participants
Extension Phase: Percentage of Participants With Clinical Benefit as Assessed by the Investigator During the Extension Phase
ParticipantsAll Patients in Extension Phase
Extension Cycle 1 Day 18
Extension Cycle 2 Day 17
Extension Cycle 3 Day 17
Extension Cycle 4 Day 16
Extension Cycle 5 Day 18
Extension Cycle 6 Day 17
Extension Cycle 7 Day 17
Extension Cycle 8 Day 16
Extension Cycle 9 Day 17
Extension Cycle 10 Day 15
Extension Cycle 11 Day 14
Extension Cycle 12 Day 17
Extension Cycle 13 Day 14
Extension Cycle 14 Day 15
Extension Cycle 15 Day 14
Extension Cycle 16 Day 13
Extension Cycle 17 Day 13
Extension Cycle 18 Day 13
Extension Cycle 19 Day 13
Extension Cycle 20 Day 13
Extension Cycle 21 Day 13
Extension Cycle 22 Day 13
Extension Cycle 23 Day 13
Extension Cycle 24 Day 12
Extension Cycle 25 Day 12
Extension Cycle 26 Day 12
Extension Cycle 27 Day 12
Extension Cycle 28 Day 12
Extension Cycle 29 Day 11

Adverse events

Collected over Adverse Events (AEs) were collected from the first dose through post-treatment follow-up, for up to 86 months. Deaths were recorded from study start through post-treatment follow-up over the same period. AE data were summarized for core phase patients from start to end of the core phase (up to 58 months) and for extension phase patients from the start of the core phase through the end of the extension phase (up to 86 months).. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Cohort A: Pre-treated With CDK 4/6i + AI (Core Phase)78/127 (61.4%)37/127 (29.1%)126/127 (99.2%)
Cohort B: Pre-treated With CDK 4/6i + Fulvestrant (Core Phase)76/126 (60.3%)48/126 (38.1%)126/126 (100%)
Cohort C: Pre-treated With Systemic Chemotherapy or ET (Core Phase)67/126 (53.2%)38/126 (30.2%)124/126 (98.4%)
Cohort A: Pre-treated With CDK 4/6i + AI (Extension Phase)0/1 (0%)0/1 (0%)1/1 (100%)
Cohort B: Pre-treated With CDK 4/6i + Fulvestrant (Extension Phase)———
Cohort C: Pre-treated With Systemic Chemotherapy or ET (Extension Phase)1/10 (10%)3/10 (30%)10/10 (100%)
Most frequent serious events
Showing 10 of 101
Most frequent serious events
EventCohort A: Pre-treated With CDK 4/6i + AI (Core Phase)Cohort B: Pre-treated With CDK 4/6i + Fulvestrant (Core Phase)Cohort C: Pre-treated With Systemic Chemotherapy or ET (Core Phase)Cohort A: Pre-treated With CDK 4/6i + AI (Extension Phase)Cohort B: Pre-treated With CDK 4/6i + Fulvestrant (Extension Phase)Cohort C: Pre-treated With Systemic Chemotherapy or ET (Extension Phase)
Colitis ulcerativeGastrointestinal disorders0/1270/1261/1260/1—1/10
Ankle fractureInjury, poisoning and procedural complications0/1271/1260/1260/1—1/10
Migraine with auraNervous system disorders0/1270/1261/1260/1—1/10
HyperglycaemiaMetabolism and nutrition disorders7/1273/1262/1260/1—0/10
Abdominal painGastrointestinal disorders2/1274/1260/1260/1—0/10
PneumoniaInfections and infestations1/1274/1262/1260/1—0/10
ArthralgiaMusculoskeletal and connective tissue disorders1/1273/1261/1260/1—0/10
Back painMusculoskeletal and connective tissue disorders0/1270/1263/1260/1—0/10
Acute kidney injuryRenal and urinary disorders0/1273/1261/1260/1—0/10
DyspnoeaRespiratory, thoracic and mediastinal disorders3/1272/1262/1260/1—0/10
Most frequent other events
Showing 10 of 149
Most frequent other events
EventCohort A: Pre-treated With CDK 4/6i + AI (Core Phase)Cohort B: Pre-treated With CDK 4/6i + Fulvestrant (Core Phase)Cohort C: Pre-treated With Systemic Chemotherapy or ET (Core Phase)Cohort A: Pre-treated With CDK 4/6i + AI (Extension Phase)Cohort B: Pre-treated With CDK 4/6i + Fulvestrant (Extension Phase)Cohort C: Pre-treated With Systemic Chemotherapy or ET (Extension Phase)
Dry eyeEye disorders7/1276/1265/1261/1—1/10
DiarrhoeaGastrointestinal disorders82/12786/12668/1261/1—7/10
DyspepsiaGastrointestinal disorders19/12713/12613/1261/1—2/10
Gastrointestinal painGastrointestinal disorders2/1270/1260/1261/1—0/10
NauseaGastrointestinal disorders59/12768/12651/1261/1—3/10
StomatitisGastrointestinal disorders34/12743/12638/1261/1—3/10
AstheniaGeneral disorders24/12727/12615/1261/1—2/10
Blood creatinine increasedInvestigations15/12712/1268/1261/1—2/10
Lymphocyte count decreasedInvestigations4/1272/1264/1261/1—0/10
Weight decreasedInvestigations18/12719/12623/1261/1—2/10

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Cohort A: Pre-treated With CDK 4/6i + AICohort B: Pre-treated With CDK 4/6i + FulvestrantCohort C: Pre-treated With Systemic Chemotherapy or ETTotal
<=18 years0000
Between 18 and 65 years958083258
>=65 years324643121
Sex: Female, Male
Sex: Female, Male(Participants)Cohort A: Pre-treated With CDK 4/6i + AICohort B: Pre-treated With CDK 4/6i + FulvestrantCohort C: Pre-treated With Systemic Chemotherapy or ETTotal
Female127126125378
Male0011
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Cohort A: Pre-treated With CDK 4/6i + AICohort B: Pre-treated With CDK 4/6i + FulvestrantCohort C: Pre-treated With Systemic Chemotherapy or ETTotal
Caucasian818583249
Unknown23241158
Asian1282848
Black6118
Other37313
Pacific islander1001
Missing1102
08

Study locations

94 sites
  • Banner MD Anderson Cancer Center
    Gilbert, Arizona 85234, United States
  • Mayo Clinic Arizona
    Phoenix, Arizona 85054, United States
  • Kaiser Permanente Medical Group
    Anaheim, California 92807, United States
  • Beverly Hills Cancer Center
    Beverly Hills, California 90211, United States
  • University of Calif Irvine Med Cntr
    Irvine, California 92660, United States
  • Kaiser Permanent Southern Californi
    San Diego, California 92120, United States
  • UCSF
    San Francisco, California 94115, United States
  • Yale University Yale Cancer Center
    New Haven, Connecticut 06511, United States
  • Advent Health Cancer Institute
    Orlando, Florida 32804, United States
  • University of Kansas Cancer Center
    Kansas City, Kansas 66205, United States
  • University of Louisville James Graham Brown Cancer Center
    Louisville, Kentucky 40202, United States
  • Mercy Medical Center
    Baltimore, Maryland 21202, United States
  • Greater Baltimore Med Center Cancer Center
    Baltimore, Maryland 21204, United States
  • Massachusetts General Hospital
    Boston, Massachusetts 02114, United States
  • Lahey Clinic
    Burlington, Massachusetts 01805, United States
  • Josephine Ford Cancer Center
    Detroit, Michigan 48202, United States
  • St Vincent Frontier Cancer Center
    Billings, Montana 59102, United States
  • New Mexico Cancer Care Alliance
    Albuquerque, New Mexico 87106, United States
  • Memorial Sloane Ketterin Cancer Ctr
    New York, New York 10065, United States
  • Uni Hosp of Cleveland Cancer Center
    Cleveland, Ohio 44106, United States
  • Texas Oncology
    Dallas, Texas 75246, United States
  • Cancer Care Centers of South Texas HOAST
    San Antonio, Texas 78229, United States
  • UT Health San Antonio
    San Antonio, Texas 78229, United States
  • Virginia Oncology Associates
    Norfolk, Virginia 23502, United States
  • Northwest Medical Specialists
    Tacoma, Washington 98405, United States
  • Novartis Investigative Site
    CABA, Buenos Aires C1118AAT, Argentina
  • Novartis Investigative Site
    CABA, Buenos Aires C1125ABD, Argentina
  • Novartis Investigative Site
    CABA, Buenos Aires C1426ANZ, Argentina
  • Novartis Investigative Site
    Rosario, Santa Fe Province S2000DSV, Argentina
  • Novartis Investigative Site
    Rosario, Sante Fe S200KZE, Argentina
  • Novartis Investigative Site
    La Rioja, 5300, Argentina
  • Novartis Investigative Site
    Leuven, 3000, Belgium
  • Novartis Investigative Site
    Liège, 4000, Belgium
  • Novartis Investigative Site
    Vancouver, British Columbia V5Z 4E6, Canada
  • Novartis Investigative Site
    Halifax, Nova Scotia B3H 2Y9, Canada
  • Novartis Investigative Site
    Kitchener, Ontario N2G 1G3, Canada
  • Novartis Investigative Site
    Toronto, Ontario M5B 1N9, Canada
  • Novartis Investigative Site
    Temuco, Araucania 4810469, Chile
  • Novartis Investigative Site
    Santiago, 7500921, Chile
  • Novartis Investigative Site
    Santiago, 8420383, Chile
  • Novartis Investigative Site
    Odense C, 5000, Denmark
  • Novartis Investigative Site
    Vejle, DK-7100, Denmark
  • Novartis Investigative Site
    Nice, Alpes Maritimes 06189, France
  • Novartis Investigative Site
    Saint-Cloud, Hauts De Seine 92210, France
  • Novartis Investigative Site
    Bordeaux, 33076, France
  • Novartis Investigative Site
    Caen, 14021, France
  • Novartis Investigative Site
    Lille, 59020, France
  • Novartis Investigative Site
    Lyon, 69373, France
  • Novartis Investigative Site
    Montpellier, 34298, France
  • Novartis Investigative Site
    Saint-Herblain, 44805, France
  • Novartis Investigative Site
    Strasbourg, 67000, France
  • Novartis Investigative Site
    Toulouse, 31059, France
  • Novartis Investigative Site
    Dresden, Saxony 01307, Germany
  • Novartis Investigative Site
    Augsburg, 86150, Germany
  • Novartis Investigative Site
    Berlin, 14169, Germany
  • Novartis Investigative Site
    Erlangen, 91054, Germany
  • Novartis Investigative Site
    Essen, 45136, Germany
  • Novartis Investigative Site
    Heidelberg, 69120, Germany
  • Novartis Investigative Site
    Ulm, 89081, Germany
  • Novartis Investigative Site
    Delhi, 110085, India
  • Novartis Investigative Site
    Petah Tikva, 4941492, Israel
  • Novartis Investigative Site
    Ramat Gan, 5265601, Israel
  • Novartis Investigative Site
    Rehovot, 7661041, Israel
  • Novartis Investigative Site
    Tel Aviv, 6423906, Israel
  • Novartis Investigative Site
    Ancona, AN 60126, Italy
  • Novartis Investigative Site
    Bergamo, BG 24127, Italy
  • Novartis Investigative Site
    Bologna, BO 40138, Italy
  • Novartis Investigative Site
    Genova, GE 16132, Italy
  • Novartis Investigative Site
    Milan, MI 20133, Italy
  • Novartis Investigative Site
    Milan, MI 20141, Italy
  • Novartis Investigative Site
    Roma, RM 00168, Italy
  • Novartis Investigative Site
    Naples, 80131, Italy
  • Novartis Investigative Site
    Osaka, Osaka 540-0006, Japan
  • Novartis Investigative Site
    Jalisco, 45640, Mexico
  • Novartis Investigative Site
    Maastricht, Limburg 6229 HX, Netherlands
  • Novartis Investigative Site
    Singapore, 168583, Singapore
  • Novartis Investigative Site
    Singapore, 217562, Singapore
  • Novartis Investigative Site
    Seoul, Korea 03080, South Korea
  • Novartis Investigative Site
    Seoul, 06351, South Korea
  • Novartis Investigative Site
    L'Hospitalet de Llobregat, Barcelona 08907, Spain
  • Novartis Investigative Site
    Salamanca, Castille and León 37007, Spain
  • Novartis Investigative Site
    Barcelona, Catalonia 08035, Spain
  • Novartis Investigative Site
    Barcelona, 08036, Spain
  • Novartis Investigative Site
    Castellon, 12002, Spain
  • Novartis Investigative Site
    Madrid, 28041, Spain
  • Novartis Investigative Site
    Seville, 41013, Spain
  • Novartis Investigative Site
    Tainan, 70403, Taiwan
  • Novartis Investigative Site
    Taipei, 10002, Taiwan
  • Novartis Investigative Site
    Taipei, 103616, Taiwan
  • Novartis Investigative Site
    Edinburgh, Scotland EH4 2XU, United Kingdom
  • Novartis Investigative Site
    Sutton, Surrey SM2 5PT, United Kingdom
  • Novartis Investigative Site
    Leicester, LE2 7LG, United Kingdom
  • Novartis Investigative Site
    London, SW3 6JJ, United Kingdom
  • Novartis Investigative Site
    Nottingham, NG5 1PB, United Kingdom
09

References and documents

Publications

  • Rugo HS, Lerebours F, Ciruelos E, Drullinsky P, Ruiz-Borrego M, Neven P, Park YH, Prat A, Bachelot T, Juric D, Turner N, Sophos N, Zarate JP, Arce C, Shen YM, Turner S, Kanakamedala H, Hsu WC, Chia S. Alpelisib plus fulvestrant in PIK3CA-mutated, hormone receptor-positive advanced breast cancer after a CDK4/6 inhibitor (BYLieve): one cohort of a phase 2, multicentre, open-label, non-comparative study. Lancet Oncol. 2024 Dec;25(12):e629-e638. doi: 10.1016/S1470-2045(24)00673-9. PubMed 39637900 ↗
  • Borrego MR, Lu YS, Reyes-Cosmelli F, Park YH, Yamashita T, Chiu J, Airoldi M, Turner N, Fein L, Ghaznawi F, Singh J, Pantoja K, Schnell C, Akdere M, Chia S. SGLT2 inhibition improves PI3Kalpha inhibitor-induced hyperglycemia: findings from preclinical animal models and from patients in the BYLieve and SOLAR-1 trials. Breast Cancer Res Treat. 2024 Nov;208(1):111-121. doi: 10.1007/s10549-024-07405-8. Epub 2024 Aug 23. PubMed 39177931 ↗
  • Rodon J, Demanse D, Rugo HS, Burris HA, Simo R, Farooki A, Wellons MF, Andre F, Hu H, Vuina D, Quadt C, Juric D. A risk analysis of alpelisib-induced hyperglycemia in patients with advanced solid tumors and breast cancer. Breast Cancer Res. 2024 Mar 4;26(1):36. doi: 10.1186/s13058-024-01773-1. PubMed 38439079 ↗
  • Rugo HS, Lerebours F, Ciruelos E, Drullinsky P, Ruiz-Borrego M, Neven P, Park YH, Prat A, Bachelot T, Juric D, Turner N, Sophos N, Zarate JP, Arce C, Shen YM, Turner S, Kanakamedala H, Hsu WC, Chia S. Alpelisib plus fulvestrant in PIK3CA-mutated, hormone receptor-positive advanced breast cancer after a CDK4/6 inhibitor (BYLieve): one cohort of a phase 2, multicentre, open-label, non-comparative study. Lancet Oncol. 2021 Apr;22(4):489-498. doi: 10.1016/S1470-2045(21)00034-6. PubMed 33794206 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2017 to primary completion in Jun 2021, 45 months.

Results were first posted in Mar 2024, 2 years 9 months after primary completion. A results delay was requested in May 2022.

Of 232 industry-sponsored phase 2 interventional studies under Breast Neoplasms, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 53. This study's 45 months is above that.

Counting every sponsor, half of 1,302 studies reached it within 51 months; a quarter within 30 and three quarters within 82.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 15, 2017
First posted
Feb 17, 2017
StartActual
Aug 29, 2017
Primary completionActual
Jun 14, 2021
CompletionActual
Nov 12, 2024
Results delay requested
May 13, 2022
Results first posted
Mar 27, 2024
Last update
Jan 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 13, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03056755
Responsible party
Sponsor
First posted
Feb 17, 2017
Start date
Aug 29, 2017
Primary completion
Jun 14, 2021
Completion
Nov 12, 2024
Results posted
Mar 27, 2024
Last update
Jan 13, 2026

Study contacts

Novartis Pharmaceuticals
study director · Novartis Pharmaceuticals

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Alpelisib · Letrozole

Start the discussion